Strategic partnership Natus Medical Incorporated has partnered with Persyst to integrate AI-powered seizure detection algorithms, signaling potential co-selling opportunities and expanded product integration channels for selling to neurodiagnostic and hospital networks.

FDA pathway Persyst seizure detection technology is under FDA 510(k) review, indicating a forthcoming regulatory milestone that could open additional sales channels with healthcare providers seeking compliant, market-ready solutions.

Market leadership Persyst asserts leadership as the world’s leading supplier of seizure and spike detection software for continuous, long-term and ambulatory EEG, presenting a strong credibility signal for enterprise EEG manufacturers and hospital systems.

Growth potential With revenue in the mid range of tens of millions and a specialized product suite, Persyst offers opportunities to expand into additional EEG monitoring segments, including OEM collaborations and bundled analytics offerings.

Industry alignment The collaboration with a major EEG equipment partner and a focus on AI-driven analysis aligns with market trends toward automated, AI-enhanced neurodiagnostic workflows, presenting cross-sell and upsell opportunities to existing customers and adjacent markets.